Different batches [Regulatives / Guidelines]

posted by wienui  – Germany, Oman, 2020-03-08 10:19 (587 d 11:39 ago) – Posting: # 21225
Views: 2,840

Hi Marcelo,

» I agree with you. It was just a suggestion based on our previous experience in Brazil :-|. Sometimes we need to explain the inexplicable to health authority to avoid delays in the dossier review :-D

The use of a different batch in the fed study as asked above from taiyab.jameel could be better as you can prove batches therpeutic equivalence consistency via in vivo studies.

On the contrary, in the case of additional strength biowaiver, it is a must to use the same biobatch for which the therpeutic equivalence was proven before via in vivo BE study.

Best regards,

Cheers,
Osama

Complete thread:

Activity
 Admin contact
21,729 posts in 4,543 threads, 1,543 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Saturday 22:58 CEST (Europe/Vienna)

If you want to converse with me,
define your terms.    Voltaire

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5